J. Pablo Abonia, MD
Interim Director, Registry for Eosinophilic Disorders (REGID)
Academic Information
Associate Professor, UC Department of Pediatrics
Show All
Specialties
Eosinophilic and mast cell disorders; immunodeficiency
Biography
J. Pablo Abonia, MD, provides the bulk of the clinical allergy care for patients with eosinophilic disease. He is currently involved in a multicenter clinical research trial of anti-IL5 (reslizumab) for patients with eosinophilic esophagitis. His research focuses on mining the research databanks (patient characteristics, tissue samples, RNA and DNA) to elucidate the mechanisms, diagnosis and treatment of eosinophilic esophagitis, and he is the Interim Director of the Registry for Eosinophilic Disorders (REGID). He is particularly interested in the role of mast cells in eosinophilic esophagitis.
Education and Training
MD: University of Buffalo, Buffalo, NY, 1997. Residency: Pediatrics, Children's Hospital of Buffalo, Buffalo, NY, 2000. Certification: American Board of Pediatrics, 2001; American Board of Allergy and Immunology, 2003.
Publications
View PubMed Publications
Abonia JP, Rothenberg ME. Eosinophilic esophagitis: rapidly advancing insights. Annu Rev Med. 2012;63:421-34. Spergel JM, Rothenberg ME, Collins MH, Furuta GT, Markowitz JE, Fuchs G 3rd, O'Gorman MA, Abonia JP, Young J, Henkel T, Wilkins HJ, Liacouras CA. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2012 Feb;129(2):456-63. Lu TX, Sherrill JD, Wen T, Plassard AJ, Besse JA, Abonia JP, Franciosi JP, Putnam PE, Eby M, Martin LJ, Aronow BJ, Rothenberg ME. MicroRNA signature in patients with eosinophilic esophagitis, reversibility with glucocorticoids, and assessment as disease biomarkers. J Allergy Clin Immunol. 2012 Apr;129(4):1064-75. Henderson CJ, Abonia JP, King EC, Putnam PE, Collins MH, Franciosi JP, Rothenberg ME. Comparative dietary therapy effectiveness in remission of pediatric eosinophilic esophagitis. J Allergy Clin Immunol. 2012 Jun;129(6):1570-8. Franciosi JP, Hommel KA, DeBrosse CW, Greenberg AB, Greenler AJ, Abonia JP, Rothenberg ME, Varni JW. Quality of life in paediatric eosinophilic oesophagitis: what is important to patients? Child Care Health Dev. 2012 Jul;38(4):477-83. Franciosi JP, Hommel KA, Greenberg AB, Debrosse CW, Greenler AJ, Abonia JP, Rothenberg ME, Varni JW. Development of the Pediatric Quality of Life Inventory Eosinophilic Esophagitis Module items: qualitative methods. BMC Gastroenterol. 2012 Sep 25;12(1):135. Abonia JP, Putnam PE. Mepolizumab in eosinophilic disorders. Expert Rev Clin Immunol. 2011 Jul;7(4):411-7. Debrosse CW, Franciosi JP, King EC, Buckmeier Butz BK, Greenberg AB, Collins MH, Abonia JP, Assa'ad A, Putnam PE, Rothenberg ME. Long-term outcomes in pediatric-onset esophageal eosinophilia. J Allergy Clin Immunol. 2011 Jul;128(1):132-8.
Abonia JP, Castells M. Drug allergy in pediatric patients. Pediatr Ann. 2011 Apr;40(4):200-4. Franciosi JP, Hommel KA, DeBrosse CW, Greenberg AB, Greenler AJ, Abonia JP, Rothenberg ME, Varni JW. Development of a validated patient-reported symptom metric for pediatric eosinophilic esophagitis: qualitative methods. BMC Gastroenterol. 2011 Nov 18;11:126.
|
Amal H. Assa'ad, MD
Director, Clinical Services
centers her research on food allergy and asthma. Addressing the occult effect of allergic sensitization to foods on the bronchial hyperresponsiveness in asthmatic patients and the genetic basis of food allergy. Participates in research of investigational drugs in asthma and immunodeficiencies. Working with division investigators on a translational research program that will bring basic research to the bedside in atopic and eosinophilic diseases.
513-636-6771
amal.assa'ad@cchmc.org
Amal H. Assa'ad, MD
Director, Clinical Services
Academic Information
Professor, UC Department of Pediatrics
Show All
Specialties
Food allergy; asthma; vaccine allergy; immunodeficiencies
Education and Training
MBBCh (MD): Ain Shams University, Cairo, Egypt 1978. MS: Ain Shams University, Cairo, Egypt, 1982. Residency: Internal Medicine/Pediatrics, Michigan State University, Hurley Medical Center, Flint, Mich.; Internal Medicine/Pediatrics, Wright State University, Dayton, Ohio, 1990-1992.
Fellowship: Allergy/Clinical Immunology, University of Texas Health Science Center, San Antonio, Texas, 1986-1987; Allergy/Clinical Immunology, Children's Hospital Medical Center, Cincinnati, Ohio, 1992-1995.
Certification: American Board of Internal Medicine, 1992; American Board of Pediatrics, 1992; American Board of Allergy and Immunology, 1995.
Publications
View PubMed Publications
Sherrill JD, Gao PS, Stucke EM, Blanchard C, Collins MH, Putnam PE, Franciosi JP, Kushner JP, Abonia JP, Assa'ad AH, Kovacic MB, Biagini Myers JM, Bochner BS, He H, Hershey GK, Martin LJ, Rothenberg ME. Variants of thymic stromal lymphopoietin and its receptor associate with eosinophilic esophagitis. J Allergy Clin Immunol. 2010 Jul;126(1):160-5.e3. DeBrosse CW, Collins MH, Buckmeier Butz BK, Allen CL, King EC, Assa'ad AH, Abonia JP, Putnam PE, Rothenberg ME, Franciosi JP. Identification, epidemiology, and chronicity of pediatric esophageal eosinophilia, 1982-1999. J Allergy Clin Immunol. 2010 Jul;126(1):112-9. Assa'ad A. Eosinophilic gastrointestinal disorders. Allergy Asthma Proc. 2009 Jan-Feb;30(1):17-22. Assa'ad A. Gastrointestinal eosinophil-mediated disorders and their treatment. Curr Allergy Asthma Rep. 2009 Jan;9(1):26-9.
Collins MH, Blanchard C, Abonia JP, Kirby C, Akers R, Wang N, Putnam PE, Jameson SC, Assa'ad AH, Konikoff MR, Stringer KF, Rothenberg ME. Clinical, pathologic, and molecular characterization of familial eosinophilic esophagitis compared with sporadic cases. Clin Gastroenterol Hepatol. 2008 Jun;6(6):621-9. Stein ML, Villanueva JM, Buckmeier BK, Yamada Y, Filipovich AH, Assa'ad AH, Rothenberg ME. Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels. J Allergy Clin Immunol. 2008 Jun;121(6):1473-83, 1483.e1-4. Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU, Schwartz LB, Rosenwasser LJ, Ring J, Griffin EF, Haig AE, Frewer PI, Parkin JM, Gleich GJ; Mepolizumab HES Study Group. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med. 2008 Mar 20;358(12):1215-28. Gupta J, Grube E, Ericksen MB, Stevenson MD, Lucky AW, Sheth AP, Assa'ad AH, Khurana Hershey GK. Intrinsically defective skin barrier function in children with atopic dermatitis correlates with disease severity. J Allergy Clin Immunol. 2008 Mar;121(3):725-730.e2.
Assa'ad A. Eosinophilic esophagitis: association with allergic disorders. Gastrointest Endosc Clin N Am. 2008 Jan;18(1):119-32; x.
Bullock JZ, Villanueva JM, Blanchard C, Filipovich AH, Putnam PE, Collins MH, Risma KA, Akers RM, Kirby CL, Buckmeier BK, Assa'ad AH, Hogan SP, Rothenberg ME. Interplay of adaptive th2 immunity with eotaxin-3/c-C chemokine receptor 3 in eosinophilic esophagitis. J Pediatr Gastroenterol Nutr. 2007 Jul;45(1):22-31.
|
Artem Barski, PhD
Assistant Professor, Genetics and Allergy & Immunology
uses cutting-edge genomic technologies (such as ChIP-Seq and RNA-Seq) to understand contribution of epigenetic mechanisms and polymerase stalling to T cell activation, differentiation and to formation of T cell memory. Visit the Barski Lab
513-636-1851
artem.barski@cchmc.org
Artem Barski, PhD
Assistant Professor, Genetics and Allergy & Immunology
Academic Information
Assistant Professor, UC Department of Pediatrics
Show All
Specialties
Biography
Artem Barski, PhD, is interested in epigenetic and transcriptional regulation of gene expression. During his post-doctoral training in Keji Zhao lab at NIH, Dr. Barski took part in the development of ChIP-Seq, a revolutionary method that combines ChIP with the next-generation sequencing. ChIP-Seq allows genome-wide mapping of chromatin modifications and transcription factor binding sites with resolution and sensitivity far exceeding older methods. Together with his NIH colleagues Dr. Barski used this approach to map more than 40 chromatin modifications in human T cells, which fundamentally improved the understanding of epigenetic regulation of transcription. Dr. Barski has since been using ChIP-Seq and other sequencing-based genome-wide methods to understand the role of chromatin modifications in gene regulation. His most recent work includes investigation of chromatin regulation of genes transcribed by RNA Polymerase III and the discovery of gene poising in T cells. Since his arrival to Cincinnati Children’s Hospital in 2011, Dr. Barski is utilizing ChIP-Seq, RNA-Seq and other cutting-edge approaches to understand epigenetic basis of T cell activation, memory and tolerance.
Education and Training
BS/MS: Moscow State University, Department of Chemistry, Moscow, Russia, 2000.
PhD: University of Southern California, Los Angeles, CA, 2006.
Fellowship: National Institutes of Health (NIH), National Heart Lung, and Blood Institute (NHLBI), Bethesda, MD, 2011.
Publications
Barski A, Chepelev I, Liko D, Cuddapah S, Fleming AB, Birch J, Cui K, White RJ, Zhao K. Pol II and its associated epigenetic marks are present at Pol III-transcribed noncoding RNA genes. Nat Struct Mol Biol. 2010 May;17(5):629-34.
Cuddapah S, Barski A, Zhao K. Epigenomics of T cell activation, differentiation, and memory. Curr Opin Immunol. 2010 Jun;22(3):341-7. Cuddapah S, Barski A, Cui K, Schones DE, Wang Z, Wei G, Zhao K. Native chromatin preparation and Illumina/Solexa library construction. Cold Spring Harb Protoc. 2009 Jun;2009(6):pdb.prot5237.
Barski A, Jothi R, Cuddapah S, Cui K, Roh TY, Schones DE, Zhao K. Chromatin poises miRNA- and protein-coding genes for expression. Genome Res. 2009 Oct;19(10):1742-51 Barski A, Zhao K. Genomic location analysis by ChIP-Seq. J Cell Biochem. 2009 May 1;107(1):11-8.
Jothi R, Cuddapah S, Barski A, Cui K, Zhao K. Genome-wide identification of in vivo protein-DNA binding sites from ChIP-Seq data. Nucleic Acids Res. 2008 Sep;36(16):5221-31.
Wang Z, Zang C, Rosenfeld JA, Schones DE, Barski A, Cuddapah S, Cui K, Roh TY, Peng W, Zhang MQ, Zhao K. Combinatorial patterns of histone acetylations and methylations in the human genome. Nat Genet. 2008 Jul;40(7):897-903
Schones DE, Cui K, Cuddapah S, Roh TY, Barski A, Wang Z, Wei G, Zhao K. Dynamic regulation of nucleosome positioning in the human genome. Cell. 2008 Mar 7;132(5):887-98.
Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, Wei G, Chepelev I, Zhao K. High-resolution profiling of histone methylations in the human genome. Cell. 2007 May 18;129(4):823-37.
Barski A, Frenkel B. ChIP Display: novel method for identification of genomic targets of transcription factors. Nucleic Acids Res. 2004 Jul 13;32(12):e104.
Grants
Role of chromatin and gene poising in T cell differentiation and activation. Principal Investigator. National Institutes of Health. 2009 - 2004. #1K22HL098691-01.
|
Patricia C. Fulkerson, MD, PhD
researches the biology of the eosinophil-lineage committed progenitor (EoP). Aiming to identify noveltherapeutic targets to block eosinophil production for the treatment of patients with eosinophilic disorders, she investigates transcriptional regulation of EoP generation and identifies/characterizes pathways important for EoP survival, proliferation and differentiation into mature eosinophils. Visit the Fulkerson Lab website.
513-803-0973
patricia.fulkerson@cchmc.org
Patricia C. Fulkerson, MD, PhD
Academic Information
Assistant Professor, UC Department of Pediatrics
Show All
Specialties
Biography
Patricia C. Fulkerson, MD, PhD is an assistant professor of pediatrics at Cincinnati Children’s Hospital Medical Center and the University of Cincinnati College of Medicine. Her PhD under the mentorship of Dr. Marc Rothenberg was focused on the analysis of experimental allergic lung inflammation in mice. She made a series of groundbreaking observations including a novel approach to understanding the complex and coordinated interplay of the chemokine family of cytokines and eosinophils in experimental allergic lung disease. Throughout her graduate studies, Dr. Fulkerson was recognized as a top trainee in the laboratory. Nationally, she was selected for competitive awards; her most distinguished award was the Serono Ian Clark-Lewis Memorial Award, provided to a trainee for the best talk at the Keystone Symposium Chemokines & Chemokine Receptors. Locally, she has received several competitive awards and scholarships including the Physician Scientist Training Program Scholar Award, as well as prizes for participation in research forums. Upon completion of the MD/PhD program, Dr. Fulkerson completed a research-track pediatric residency. She was recognized as being an outstanding resident and was awarded the Thomas F. Boat Pediatric Pulmonology Award in her final year of residency. Dr. Fulkerson's innovation and dedication to research continued to be recognized during her allergy/immunology fellowship; she received the AAI-Life Technologies Trainee Achievement Award from the American Association of Immunologists in 2011, and she has the distinction of having achieved extramural funding during her first year of clinical fellowship, with the NIH awarding her a K08 grant on her first application. This independent funding at such an early stage is a notable accomplishment. Now, as an assistant professor, Dr. Fulkerson’s independent research program is focused on the biology of the eosinophil lineage-committed progenitor (EoP). Her overall aim is to identify novel therapeutic targets to block eosinophil production for the treatment of patients with eosinophilic disorders. She has developed a number of innovative methods to study the regulation of eosinophil development including liquid culture systems to follow differentiation of both murine and human EoPs into mature effector eosinophils. The pathways that are identified in her culture systems are tested in models of hypereosinophilia, infection, and allergic inflammation to further characterize the clinical and therapeutic potential of candidate targets.
Education and Training
MD: Medical Scientist Training Program, University of Cincinnati College of Medicine, Cincinnati, OH, 2007. PhD: Molecular Genetics, Microbiology & Immunology, University of Cincinnati College of Medicine, Cincinnati, OH, 2005. Residency: Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2010. Fellowship: Allergy and Immunology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2012.
Publications
View PubMed Publications
Wechsler ME, Fulkerson PC, Bochner BS, Gauvreau GM, Gleich GJ, Henkel T, Kolbeck R, Mathur SK, Ortega H, Patel J, Prussin C, Renzi P, Rothenberg ME, Roufosse F, Simon D, Simon HU, Wardlaw A, Weller PF, Klion AD. Novel targeted therapies for eosinophilic disorders. J Allergy Clin Immunol. 2012;130(3):563-71. Zuo L, Fulkerson PC, Finkelman FD, Mingler M, Fischetti CA, Blanchard C, Rothenberg ME. IL-13 induces esophageal remodeling and gene expression by an eosinophil-independent, IL-13R alpha 2-inhibited pathway. J Immunol. 2010;185(1):660-9. Fulkerson PC, Rothenberg ME. Origin, regulation and physiological function of intestinal eosinophils. Best Pract Res Clin Gastroenterol. 2008;22(3):411-23. Mishra A, Wang M, Pemmaraju VR, Collins MH, Fulkerson PC, Abonia JP, Blanchard C, Putnam PE, Rothenberg ME. Esophageal remodeling develops as a consequence of tissue specific IL-5-induced eosinophilia. Gastroenterology. 2008;134(1):204-14. Fulkerson PC, Fischetti CA, Rothenberg ME. Eosinophils and CCR3 regulate interleukin-13 transgene-induced pulmonary remodeling. Am J Pathol. 2006;169(6):2117-26. Fulkerson PC, Fischetti CA, McBride ML, Hassman LM, Hogan SP, Rothenberg ME. A central regulatory role for eosinophils and the eotaxin/CCR3 axis in chronic experimental allergic airway inflammation. Proc Natl Acad Sci U S A. 2006;103(44):16418-23. Blanchard C, Wang N, Stringer KF, Mishra A, Fulkerson PC, Abonia JP, Jameson SC, Kirby C, Konikoff MR, Collins MH, Cohen MB, Akers R, Hogan SP, Assa'ad AH, Putnam PE, Aronow BJ, Rothenberg ME. Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. J Clin Invest. 2006;116(2):536-47. Fulkerson PC, Zhu H, Williams DA, Zimmermann N, Rothenberg ME. CXCL9 inhibits eosinophil responses by a CCR3- and Rac2-dependent mechanism. Blood. 2005;106(2):436-43. Fulkerson PC, Zimmermann N, Brandt EB, Muntel EE, Doepker MP, Kavanaugh JL, Mishra A, Witte DP, Zhang H, Farber JM, Yang M, Foster PS, Rothenberg ME. Negative regulation of eosinophil recruitment to the lung by the chemokine monokine induced by IFN-gamma (Mig, CXCL9). Proc Natl Acad Sci U S A. 2004;101(7):1987-92.
Grants
Role of Spi-C in Eosinophil Development and Functional Responses. Principal Investigator. National Institutes of Health. Apr 2011-Mar 2016. K08 KAI093573A.
|
Simon P. Hogan, PhD
Director of Admissions, Immunobiology Graduate Program
Academic Information
Associate Professor, UC Department of Pediatrics
Show All
Specialties
Allergies; food allergies; eosinophil biology; gastrointestinal inflammation Visit the Hogan Lab.
Education and Training
BSC: Australian National University, Canberra, Australia, 1998.
PhD: John Curtin School of Medical Research, Australian National University, Canberra, Australia, 1998.
Publications
View PubMed Publications
Munitz A, Cole ET, Beichler A, Groschwitz K, Ahrens R, Steinbrecher K, Willson T, Han X, Denson L, Rothenberg ME, Hogan SP. Paired immunoglobulin-like receptor B (PIR-B) negatively regulates macrophage activation in experimental colitis. Gastroenterology. 2010 Aug;139(2):530-41. Osterfeld H, Ahrens R, Strait R, Finkelman FD, Renauld JC, Hogan SP. Differential roles for the IL-9/IL-9 receptor alpha-chain pathway in systemic and oral antigen-induced anaphylaxis. J Allergy Clin Immunol. 2010 Feb;125(2):469-476.e2. Finkelman FD, Hogan SP, Hershey GK, Rothenberg ME, Wills-Karp M. Importance of cytokines in murine allergic airway disease and human asthma. J Immunol. 2010 Feb 15;184(4):1663-74. Review. Groschwitz KR, Ahrens R, Osterfeld H, Gurish MF, Han X, Abrink M, Finkelman FD, Pejler G, Hogan SP. Mast cells regulate homeostatic intestinal epithelial migration and barrier function by a chymase/Mcpt4-dependent mechanism. Proc Natl Acad Sci U S A. 2009 Dec 29;106(52):22381-6. Herbert DR, Yang JQ, Hogan SP, Groschwitz K, Khodoun M, Munitz A, Orekov T, Perkins C, Wang Q, Brombacher F, Urban JF Jr, Rothenberg ME, Finkelman FD. Intestinal epithelial cell secretion of RELM-beta protects against gastrointestinal worm infection. J Exp Med. 2009 Dec 21;206(13):2947-57. Groschwitz KR, Hogan SP. Intestinal barrier function: molecular regulation and disease pathogenesis. J Allergy Clin Immunol. 2009 Jul;124(1):3-20; quiz 21-2. Review. Munitz A, Seidu L, Cole ET, Ahrens R, Hogan SP, Rothenberg ME. Resistin-like molecule alpha decreases glucose tolerance during intestinal inflammation. J Immunol. 2009 Feb 15;182(4):2357-63. Hogan SP. Functional role of eosinophils in gastrointestinal inflammation. Immunol AllergyClin North Am. 2009 Feb;29(1):129-40, xi. Review. Munitz A, Waddell A, Seidu L, Cole ET, Ahrens R, Hogan SP, Rothenberg ME. Resistin-like molecule alpha enhances myeloid cell activation and promotes colitis. J Allergy Clin Immunol. 2008 Dec;122(6):1200-1207.e1. Ahrens R, Waddell A, Seidu L, Blanchard C, Carey R, Forbes E, Lampinen M, Wilson T, Cohen E, Stringer K, Ballard E, Munitz A, Xu H, Lee N, Lee JJ, Rothenberg ME, Denson L, Hogan SP. Intestinal macrophage/epithelial cell-derived CCL11/eotaxin-1 mediates eosinophil recruitment and function in pediatric ulcerative colitis. J Immunol. 2008 Nov 15;181(10):7390-9.
Grants
Interleukin-9 in Experimental Intestinal Anaphylaxis. Principal Investigator. National Institute of Health. Dec 2007 - Nov 2012. #NIH RO1 A1073553-01.
|
Michelle B. Lierl, MD
Clinical Allergist, Division of Allergy and Immunology
Academic Information
UC Department of Pediatrics
Adjunct Professor of Clinical Pediatrics
Show All
Specialties
Clinical InterestsTreatment and prevention of asthma; allergic rhinitis; allergen immunotherapy; eczema; food allergy; anaphylaxis; suspected immune deficiency Research InterestsRole of environmental allergens and pollutants in childhood asthma; allergen immunotherapy; asthma pathogenesis and treatment; role of outdoor fungal spores as aeroallergens; diagnosis and treatment of food allergy Visit Dr. Lierl's fungal spore photo website.
Biography
Michelle B. Lierl, MD, is board-certified in Pediatrics, Pediatric Pulmonary Medicine and Allergy / Immunology. Dr. Lierl's primary clinical interests are diagnosis and treatment of asthma, allergic rhinitis, chronic cough, food, latex, insect venom and drug allergies, and eczema. Dr. Lierl has been treating allergy patients in the Allergy Clinic and Asthma Center, which provides state-of-the-art diagnosis and treatment of asthma and allergies, as well as comprehensive patient education regarding these diseases. She has developed community outreach and patient / family education programs for urban children with asthma and their families. Dr. Lierl also helps staff the Allergy inpatient service, which provides consultation for the management of patients with difficult-to-manage asthma, suspected drug allergies, anaphylaxis, or suspected immune deficiency.
Education and Training
MD: University of Kentucky College of Medicine, Lexington, KY, 1979.
Residency: University of Kentucky Medical Center, Lexington, KY, 1979 to 1982.
Fellowship: Pediatric Pulmonary Medicine, Louisiana State University Medical Center, Shreveport, LA, 1984 - 1986; Allergy / Immunology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 1986 - 1988.
Certification: Pediatrics, 1984; Allergy / Immunology, 1987; Pediatric Pulmonary, 1989, 1996, 2002.
Publications
View PubMed Publications
Lierl MB. Management of mild to moderate pediatric asthma. Infect Dis Child. 2011 Dec;supplement: 8-12. Lierl MB. Allergen immunotherapy: Shots for asthma, wheezing and bee sting. Ped Annals. 2011 Apr;40:192-199. Spanier AJ, Kahn RS, Hurnung RW, Lierl MB, Lanphear BP. Associations of Fraction of Exhaled Nitric Oxide with Beta Agonist Use in Children with Asthma. Pediatric Allergy, Immunology, and Pulmonology. 2011 Mar;24(1):45-50. Lanphear BP, Hornung RW, Khoury J, Yolton K, Lierl M, Kalkbrenner A. Effects of HEPA air cleaners on unscheduled asthma visits and asthma symptoms for children exposed to secondhand tobacco smoke. Pediatrics. 2011 Jan;127(1):93-101. Metz KA, Assa'ad A, Lierl MB, Backeljauw P. Allergic reaction to mecasermin. Ann Allergy Asthma Immunol. 2009;103(1):82-3. Metz KA, Johnson T, Khurana Hershey GK, Lierl MB, Seidu L, Burns K, Assa’ad A. Successful administration of cytarabine in a 16 month old girl with acute myelogenous leukemia and cytarabine syndrome. Ann Allergy, Asthma Immunol. 2009;102:173-4. Spanier AJ, Kahn RS, Hornung RW, Wang N, Sun G, Lierl MB, Lanphear BP. Environmental exposures, nitric oxide synthase genes, and exhaled nitric oxide in asthmatic children. Pediatr Pulmonol. 2009 Aug;44(8):812-9. Spanier AJ, Hornung RW, Kahn RS, Lierl MB, Lanphear BP. Seasonal variation and environmental predictors of exhaled nitric oxide in children with asthma. Pediatr Pulmonol. 2008 Jun;43(6):576-83. Lierl M. Periodic fever syndromes: a diagnostic challenge for the allergist. Allergy. 2007 Dec;62(12):1349-58. Review. Spanier AJ, Hornung R, Lierl M, Lanphear BP. Environmental exposures and exhaled nitric oxide in children with asthma. J Pediatr. 2006 Aug;149(2):220-6.
|
Santa Ono, PhD
Professor, Division of Allergy and Immunology
Dr. Ono's principal research interests focus on transcriptional regulation in the human immune system, mechanisms of mast-cell dependent inflammation on the ocular surface, and the immune component of age-related macular degeneration.
513-636-6771
santa.ono@cchmc.org
Santa Ono, PhD
Professor, Division of Allergy and Immunology
President, University of Cincinnati
Academic Information
Professor, UC Department of Pediatrics
Show All
Biography
Santa J. Ono, PhD, is a professor of pediatrics at Cincinnati Children's Hospital Medical Center and the University of Cincinnati College of Medicine.
|
Kimberly A. Risma, MD, PhD
Director, Allergy and Immunology Fellowship Program
is focused on the molecular and cellular bases of primary disorders of immune deficiency and dysregulation, especially as it relates to lymphocyte cytotoxicity. She studies the pathologic consequences of missense mutations in perforin identified in patients with hemophagocytic lymphohistiocytosis (HLH) and strives to develop novel therapies through gene therapy or small molecule chaperones.
513-636-6771
kimberly.risma@cchmc.org
Kimberly A. Risma, MD, PhD
Director, Allergy and Immunology Fellowship Program
Academic Information
Assistant Professor, UC Department of Pediatrics
Show All
Specialties
Clinical InterestsImmune deficiency; immune dysregulation Research InterestsPathophysiology of perforin missense mutations identified in individuals with hemophagocytic lymphohistiocytosis; molecular mechanisms of primary immune deficiency and dysregulation; natural killer cell and cytotoxic T lymphocyte cytotoxicity
Biography
Kimberly Risma, MD, PhD, is an assistant professor in the Division of Allergy and Immunology at Cincinnati Children’s and the University of Cincinnati College of Medicine. Dr. Risma graduated magna cum laude with a Bachelor of Arts in Chemistry from Duke University in 1990 and was elected into The Phi Beta Kappa Society. She then matriculated at Case Western Reserve University (CWRU) School of Medicine in the Medical Scientist Training Program (MSTP). In 1996, she completed a PhD in pharmacology. She was selected by the leadership of the CWRU MSTP as the recipient of the 1997 Martin Wahl Memorial Fund Award, given annually to recognize the graduating MD, PhD student who has demonstrated the highest level of independence in research and excellence in research and clinical skills. She was also elected to Alpha Omega Alpha Society in 1997. In 1997, she enrolled in a Pediatrics residency at Cincinnati Children’s Hospital Medical Center/University of Cincinnati. During the residency program, Dr. Risma was awarded the pediatric resident teaching award by the medical students. She also engaged in translational research studies related to the genetics of asthma under the mentorship of Dr. Gurjit Hershey, resulting in a first author publication as a pediatric resident. In 2000, Dr. Risma was accepted to the Allergy and Immunology Fellowship Program at Cincinnati Children’s. In addition to her clinical training, she pursued an innovative research project under the mentorship of Dr. Janos Sumegi and Dr. Alexandra Filipovich. She proposed a mechanism to study the structural and functional impact of perforin missense mutations identified in patients with hemophagocytic lymphohistiocytosis. In 2004 she was awarded the Nezelof Prize for best scientific presentation at the international meeting of the Histiocyte Society. The culmination of her fellowship research project was published in the Journal of Clinical Investigation, 2006. Upon completion of her fellowship in 2005, Dr. Risma was appointed as an Assistant Professor in the Division of Allergy and Immunology at Cincinnati Children’s Hospital Medical Center. In 2006 Dr. Risma received a Clinical Scientist Development Award from the Doris Duke Charitable Foundation. Dr. Risma is the director of the Allergy and Immunology Fellowship Program at Cincinnati Children's, having served in this leadership position since August of 2012.
Dr. Risma's research program focuses on understanding the molecular mechanisms of immunodeficiency and immune dysregulation in children, especially as it relates to disorders of lymphocyte cytotoxicity. In addition to her research, she sees patients from all around the country in consultation for primary immune deficiency, immune dysregulation, and allergic disorders.
Education and Training
MD: Case Western Reserve University School of Medicine, Cleveland, OH, 1997. PhD: Case Western Reserve University School of Medicine, Cleveland, OH, 1996. Residency: Pediatrics, Cincinnati Children's Hospital Medical Center, 1997-2000. Fellowship: Allergy / Immunology, Cincinnati Children's Hospital Medical Center. Certification: Pediatrics, 2007; Allergy and Immunology, 2005.
Publications
View PubMed Publications
Risma K. A loss of naivete. Blood. 2012 Apr 12;119(15):3371-2. Risma K, Jordan MB. Hemophagocytic lymphohistiocytosis: updates and evolving concepts. Curr Opin Pediatr. 2012 Feb;24(1):9-15. Uygungil B, Assa'Ad A, Khurana Hershey GK, Risma K. Immunodeficiency: a problem with the faucet or the drain? Ann Allergy Asthma Immunol. 2011 Dec;107(6):547-9. Zhang K, Jordan MB, Marsh RA, Johnson JA, Kissell D, Meller J, Villanueva J, Risma KA, Wei Q, Klein PS, Filipovich AH. Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH. Blood. 2011 Nov 24;118(22):5794-8. Lykens JE, Terrell CE, Zoller EE, Risma K, Jordan MB. Perforin is a critical physiologic regulator of T-cell activation. Blood. 2011 Jul 21;118(3):618-26. Sumegi J, Barnes MG, Nestheide SV, Molleran-Lee S, Villanueva J, Zhang K, Risma KA, Grom AA, Filipovich AH. Gene expression profiling of peripheral blood mononuclear cells from children with active hemophagocytic lymphohistiocytosis. Blood. 2011 Apr 14;117(15):e151-60. Uygungil B, Bleesing JJ, Risma KA, McNeal MM, Rothenberg ME. Persistent rotavirus vaccine shedding in a new case of severe combined immunodeficiency: A reason to screen. J Allergy Clin Immunol. 2010 Jan;125(1):270-1. Marsh RA, Villanueva J, Kim MO, Zhang K, Marmer D, Risma KA, Jordan MB, Bleesing JJ, Filipovich AH. Patients with X-linked lymphoproliferative disease due to BIRC4 mutation have normal invariant natural killer T cell populations. Clin Immunol. 2009 Jul;132(1):116-23. Marsh RA, Villanueva J, Zhang K, Snow AL, Su HC, Madden L, Mody R, Kitchen B, Marmer D, Jordan MB, Risma KA, Filipovich AH, Bleesing JJ. A rapid flow cytometric screening test for X-linked lymphoproliferative disease due to XIAP deficiency. Cytometry B Clin Cytom. 2009 Sep;76(5):334-44. Risma KA, Frayer RW, Filipovich AH, Sumegi J. Aberrant maturation of mutant perforin underlies the clinical diversity of hemophagocytic lymphohistiocytosis. J Clin Invest. 2006 Jan;116(1):182-92.
|
Joseph D. Sherrill, PhD
is a molecular geneticist who has a diverse research background in microbiology, immunology and genetics. His current research employs a functional genomics approach to understand the genetic etiology of inflammatory diseases such as eosinophilic gastrointestinal disorders. In particular, his lab is focused on the discovery of disease-associated genetic variants and characterizing the biological impact of such variants using various in vitro and in vivo model systems.
513-803-0975
joseph.sherrill@cchmc.org
Joseph D. Sherrill, PhD
Academic Information
Instructor, UC Department of Pediatrics
Show All
Biography
Dr. Sherrill first joined the Division of Allergy and Immunology as a research fellow in Dr. Marc Rothenberg’s lab where he began dissecting the genetic contribution of epithelial-derived genes to the pathogenesis of eosinophilic esophagitis (EoE). The central hypothesis of his studies is that single-nucleotide polymorphisms (SNP)s in epithelial-derived genes are contributory factors in the genetic and mechanistic development of EoE. His studies culminated in two first author publications in Nature Genetics and the Journal of Allergy and Clinical Immunology that identified EoE risk variants in the TSLP gene and its receptor. Dr. Sherrill is continuing to utilize his experience gained in modern genetic techniques (genome-wide association studies, exome sequencing, and RNA sequencing) and bioinformatics to investigate eosinophilic disease risk variants as the focus of his lab.
Recognized as a promising junior faculty member, Dr. Sherrill has received a T32 training grant, the Thrasher Research Fund Early Career Award and is a recipient of the NIH Loan Repayment Program as well as numerous travel awards from the American Academy of Allergy, Asthma, and Immunology and the American Partnership for Eosinophilic Disorders. Dr. Sherrill also received the top place award at the 2011 Digestive Health Center poster symposium for his work on desmoglein-1 in eosinophilic esophagitis.
Education and Training
PhD: University of Cincinnati, Cincinnati, OH, 2008. Research Fellowship: Division of Allergy and Immunology, Cincinnati Children’s, Cincinnati, OH, 2008-2012.
Publications
View PubMed Publications
Sherrill JD, Rothenberg ME. Genetic dissection of eosinophilic esophagitis provides insight into disease pathogenesis and treatment strategies. Journal of Allergy and Clinical Immunology. 2011;128(1):23-32. Sherrill JD, Gao P, Stucke EM, Blanchard C, Collins MH, Putnam PE, Franciosi JP, Kushner JP, Abonia JP, Assa’ad AH, Butsch Kovacic M, Biagini Meyers JM, Bochner BS, He H, Khurana Hershey G, Martin LJ, Rothenberg ME. Variants of thymic stromal lymphopoietin and its receptor associate with eosinophilic esophagitis. Journal of Allergy and Clinical Immunology. 2010;126(1):160-5. Rothenberg ME*, Spergel JM*, Sherrill JD*, Annaiah K*, Martin LJ*, Cianferoni A, Gober L, Kim C, Glessner J, Frackelton E, Thomas K, Blanchard C, Liacouras C, Verma R, Aceves S, Collins MH, Brown-Whitehorn T, Putnam PE, Franciosi JP, Chiavacci RM, Grant SF, Abonia JP, Sleiman PM, Hakonarson H. Common variants at 5q22 associate with pediatric eosinophilic esophagitis. Nature Genetics. 2010;42(4):289-91.
*co-first author Sherrill JD, Stropes MP, Schneider OD, Koch DE, Bittencourt FM, Miller JLC, Miller WE. Activation of intracellular signaling pathways by the murine cytomegalovirus G protein-coupled receptor M33 occurs via PLC-beta/PKC-dependent and -independent mechanisms. Journal of Virology. 2009;83(16):8141-52. Sherrill JD, Miller, WE. Desensitization of Herpes-virus-encoded G protein-coupled receptors. Life Sciences. 2007;82(3-4):125-34. Sherrill JD, Miller WE. G protein-coupled receptor (GPCR) kinase 2 regulates agonist-independent Gq/11 signaling from the mouse cytomegalovirus GPCR M33. Journal of Biological Chemistry. 2006;281(52):39796-805.
Grants
Genetic dysregulation of desmoglein-1 enhances allergic sensitization in eosinophilic esophagitis. Principal Investigator. Thrasher Research Fund Early Career Award. 2012.
|
Yui-Hsi Wang, PhD
investigates the mechanisms that govern the plasticity of tissue resident TH2 memory / effector cells in the airway and gut. Particularly interested in understanding how inflammatory mediators, such as IL-1b, IL-33 and IL-25, regulate the development of IL-17-producing TH2 or IL-9-producing TH2 cells during airway or gastrointestinal allergic inflammation, respectively.
513-803-2193
yui_hsi.wang@cchmc.org
Yui-Hsi Wang, PhD
Academic Information
Assistant Professor, UC Department of Pediatrics
Show All
Specialties
Asthma; food allergy; T cell biology
Education and Training
PhD: University of Alabama, Birmingham, AL, 2001.
Publications
View PubMed Publications
Wang YH, Voo KS, Liu B, Chen CY, Uygungil B, Spoede W, Bernstein JA, Huston DP, Liu YJ. A novel subset of CD4(+) T(H)2 memory/effector cells that produce inflammatory IL-17 cytokine and promote the exacerbation of chronic allergic asthma. J Exp Med. 2010 Oct 25;207(11):2479-91. Shaw J, Wang YH, Ito T, Arima K, Liu YJ. Plasmacytoid dendritic cells regulate B-cell growth and differentiation via CD70. Blood. 2010 Apr 15;115(15):3051-7.
Wang YH, Liu YJ. Thymic stromal lymphopoietin, OX40-ligand, and interleukin-25 in allergic responses. Clin Exp Allergy. 2009 Jun;39(6):798-806.
Voo KS, Wang YH, Santori FR, Boggiano C, Wang YH, Arima K, Bover L, Hanabuchi S, Khalili J, Marinova E, Zheng B, Littman DR, Liu YJ. Identification of IL-17-producing FOXP3+ regulatory T cells in humans. Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4793-8.
Lu N, Wang YH, Wang YH, Arima K, Hanabuchi S, Liu YJ. TSLP and IL-7 use two different mechanisms to regulate human CD4+ T cell homeostasis. J Exp Med. 2009 Sep 28;206(10):2111-9.
Esashi E, Wang YH, Perng OA, Qin XF, Hennighausen L, Liu YJ, Watowich SS. Differential regulation of plasmacytoid and conventional dendritic cell development by GM-CSF through STAT5. Immunity. 2008;28:1-12.
Wang YH, Liu YJ. The IL-17 cytokine family and their role in allergic inflammation. Curr Opin Immunol. 2008 Dec;20(6):697-702.
Wang YH, Liu YJ. OX40-OX40L interactions: a promising therapeutic target for allergic diseases?J Clin Invest. 2007 Dec;117(12):3655-7. Wang YH, Angkasekwinai P, Meng Q, Lu N, Voo KS, Arima K, Hanabuchi S, Corrigan CG, Lee T, Dong C, Huston DR, Yao Z, Ying S, and Liu YJ. IL-25 mediated cross talk between eosinophils and TSLP-DC-activated TH2 memory cells augments allergic immune responses. J. Exp. Med. 2007;204(8): 1837-1847.
Ito T, Wang YH, Duramad O, Hanabuchi S, Perng OA, Gilliet M, Qin FX, Liu YJ. OX40 ligand shuts down IL-10-producing regulatory T cells. Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13138-43.
Grants
The roles of IL-17-producing TH2 memory/effector cells in allergic asthma. Principal Investigator. American Lung Association. July 2010 - June 2012. #AI-169584-N. Regulation and maintenance of TH2 memory/effector cells. Principal Investigator. National Institutes of Health. May 2010- April 2015. #R01AI090129-01.
|
Nives Zimmermann, MD
Director of MS Track, Immunobiology Graduate Program
focuses on deciphering mechanisms of allergic diseases, primarily asthma. Approaches include animal modeling and ex vivo cell and molecular biology. As eosinophils are the hallmark cell of allergic inflammation, including asthma, long-term goals include: 1) Understanding the mechanisms of eosinophilia and 2) Understanding the mechanisms of lung inflammation in homeostasis and allergic disease. Visit the Zimmermann Lab
513-636-3887
nives.zimmermann@cchmc.org
Nives Zimmermann, MD
Director of MS Track, Immunobiology Graduate Program
Academic Information
Associate Professor, UC Department of Pediatrics
Show All
Specialties
Education and Training
MD: School of Medicine, University of Zagreb; Zagreb, Croatia, 1995.
Publications
View PubMed Publications
Niese KA, Collier AR, Hajek AR, Cederbaum SD, O'Brien WE, Wills-Karp M, Rothenberg ME and Zimmermann N. Bone marrow cell derived arginase I is the major source of allergen-induced lung arginase but is not required for airway hyperresponsiveness, remodeling and lung inflammatory responses in mice. BMC Immunology. 2009;10:33. Kottyan LC, Collier AR, Cao KH, Niese KA, Hedgebeth M, Radu CG, Witte ON, Khurana Hershey G, Rothenberg ME, Zimmermann N. Eosinophil viability is increased by acidic pH in a cAMP and GPR65-dependent manner. Blood. 2009; 14(13):2774-82. Zimmermann N, McBride ML, Yamada Y, Hudson SA, Jones C, Cromie KD, Crocker PR, Rothenberg ME, Bochner BS. Siglec-F antibody administration to mice selectively reduces blood and tissue eosinophils. Allergy. 2008;63:1156-63. Bergeron C, Boulet LP, Page N, Laviolette M, Zimmermann N, Rothenberg ME, Hamid Q. Influence of cigarette smoke on the arginine pathway in asthmatic airways: increased expression of arginase I. J Allergy Clin Immunol. 2007;119:391-7. Guo JP, Nutku E, Yokoi H, Schnaar RL, Zimmermann N, Bochner BS. Siglec-8 and Siglec-F: inhibitory receptors on eosinophils, basophils and mast cells. Allergy Clin Immunol Inter – J World Allergy Org. 2007;19:54-59. Brandt EB, Zimmermann N, Muntel EE, Yamada Y, Pope SM, Mishra A, Hogan SP, Rothenberg ME. The alpha4beta7-integrin is dynamically expressed on murine eosinophils and involved in eosinophil trafficking to the intestine. Clin Exp Allergy. 2006; 36(4):543-53. Zimmermann N, Rothenberg ME. The arginine-arginase balance in asthma and lung inflammation. Eur J Pharmacol. 2006;533(1-3):253-62 Rothenberg ME, Doepker MP, Lewkowich IP, Chiaramonte MG, Stringer KF, Finkelman FD, MacLeod CL, Ellies LG and Zimmermann N. The cationic amino acid transporter 2 regulates inflammatory homeostasis in the lung. Proc Natl Acad Sci USA. 2006;103:14895 Yang M, Rangasamy D, Matthaei KI, Frew AJ, Zimmermann N, Mahalingam S, Webb DC, Tremethick DJ, Thompson PJ, Hogan SP, Rothenberg ME, Cowden WB, Foster PS. Inhibition of arginase I activity by RNA interference attenuates IL-13-induced airways hyperresponsiveness. J Immunol. 2006;177:5595-603. Fulkerson PC, Zhu H, Williams DA, Zimmermann N, Rothenberg ME. CXCL9 inhibits eosinophil responses by a CCR3- and Rac2-dependent mechanism. Blood. 2005;106(2):436-43.
|
